Your browser doesn't support javascript.
Drug-drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case-control study in the National COVID Cohort Collaborative (N3C).
Kravchenko, Olga V; Boyce, Richard D; Gomez-Lumbreras, Ainhoa; Kocis, Paul T; Villa Zapata, Lorenzo; Tan, Malinda; Leonard, Charles E; Andersen, Kathleen M; Mehta, Hemalkumar; Alexander, G Caleb; Malone, Daniel C.
  • Kravchenko OV; Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA kravchen@pitt.edu.
  • Boyce RD; Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Gomez-Lumbreras A; College of Pharmacy, University of Utah Health, Salt Lake City, Utah, USA.
  • Kocis PT; Department of Pharmacology, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, USA.
  • Villa Zapata L; College of Pharmacy, Mercer University, Atlanta, Georgia, USA.
  • Tan M; Pharmacotherapy Outcomes Research Center, The University of Utah College of Pharmacy, Salt Lake City, Utah, USA.
  • Leonard CE; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Andersen KM; Center for Drug Safety and Effectiveness, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Mehta H; Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Alexander GC; Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Malone DC; Center for Drug Safety and Effectiveness, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
BMJ Open ; 12(12): e066846, 2022 12 29.
Article in English | MEDLINE | ID: covidwho-2193799
ABSTRACT

OBJECTIVE:

The goal of this work is to evaluate if there is an increase in the risk of thromboembolic events (TEEs) due to concomitant exposure to dexamethasone and apixaban or rivaroxaban. Direct oral anticoagulants (DOACs), as well as corticosteroid dexamethasone, are commonly used to treat individuals hospitalised with COVID-19. Dexamethasone induces cytochrome P450-3A4 enzyme that also metabolises DOACs apixaban and rivaroxaban. This raises a concern about possible interaction between dexamethasone and DOACs that may reduce the efficacy of the DOACs and result in an increased risk of TEE.

DESIGN:

We used nested case-control study design.

SETTING:

This study was conducted in the National COVID Cohort Collaborative (N3C), the largest electronic health records repository for COVID-19 in the USA.

PARTICIPANTS:

Study participants were adults over 18 years who were exposed to a DOAC for 10 or more consecutive days. Exposure to dexamethasone was at least 5 or more consecutive days. PRIMARY AND SECONDARY OUTCOME

MEASURES:

Our primary exposure variable was concomitant exposure to dexamethasone for 5 or more days after exposure to either rivaroxaban or apixaban for 5 or more consecutive days. We used McNemar's Χ2 test and adjusted logistic regression to evaluate association between concomitant use of dexamethasone with either apixaban or rivaroxaban.

RESULTS:

McNemar's Χ2 test did not find a discernible association of TEE in patients concomitantly exposed to dexamethasone and a DOAC (χ2=0.5, df=1, p=0.48). In addition, a conditional logistic regression model did not find an increase in the risk of TEE (adjusted OR 1.15, 95% CI 0.32 to 4.18).

CONCLUSION:

This nested case-control study did not find evidence of an association between concomitant exposure to dexamethasone and a DOAC with an increase in risk of TEE. Due to small sample size, an association cannot be completely ruled out.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Atrial Fibrillation / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Limits: Adult / Humans Language: English Journal: BMJ Open Year: 2022 Document Type: Article Affiliation country: Bmjopen-2022-066846

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Atrial Fibrillation / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Limits: Adult / Humans Language: English Journal: BMJ Open Year: 2022 Document Type: Article Affiliation country: Bmjopen-2022-066846